Macroglossia is the medical term for an unusually large tongue. Severe enlargement of the tongue can cause cosmetic and functional difficulties in speaking, eating, swallowing and sleeping. Macroglossia is uncommon, and usually occurs in children. There are many causes. Treatment depends upon the exact cause. Signs and symptoms
Although it may be asymptomatic, symptoms usually are more likely to be present and more severe with larger tongue enlargements. Signs and symptoms include:

Dyspnea - difficult, noisy breathing, obstructive sleep apnea or airway obstruction
Dysphagia - difficulty swallowing and eating
Dysphonia - disrupted speech, possibly manifest as lisping
Sialorrhea - drooling
Angular cheilitis - sores at the corners of the mouth
Crenated tongue - indentations on the lateral borders of the tongue caused by pressure from teeth ("pie crust tongue")
Open bite malocclusion - a type of malocclusion of the teeth
Mandibular prognathism - enlarged mandible
Mouth breathing
Orthodontic abnormalities - including diastema and tooth spacingA tongue that constantly protrudes from the mouth is vulnerable to drying out, ulceration, infection or even necrosis. Causes
Macroglossia may be caused by a wide variety of congenital and acquired conditions. Isolated macroglossia has no determinable cause. The most common causes of tongue enlargement are vascular malformations (e.g. lymphangioma or hemangioma) and muscular hypertrophy (e.g. Beckwith–Wiedemann syndrome or hemihyperplasia). Enlargement due to lymphangioma gives the tongue a pebbly appearance with multiple superficial dilated lymphatic channels. Enlargement due to hemihyperplasia is unilateral.
Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only two amino acids.Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration (FDA) on June 15, 2011. References
External links
"Belatacept". Drug Information Portal. U.S. National Library of Medicine.